ATP6V0B

Across TCGA pan-cancer cohorts, ATP6V0B Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ATP6V0B data layer compared with 25 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in thyroid carcinoma (THCA), where higher ATP6V0B Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ATP6V0B expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

THCA, PRAD, and UCEC are the cancer types where ATP6V0B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THCA	DFS	Median	All	0.100	0.841	<.001	18	view →
PRAD	DFS	Median	All	0.617	0.886	.035	6	view →
UCEC	DFS	Median	All	1.000	0.631	.041	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

ATP6V0B–THCA (DFS)

Open the THCA breakdown →